|
|
||||||||||
|
J Am Coll Cardiol, 2007; 49:1490-1495, doi:10.1016/j.jacc.2007.02.035
(Published online 20 March 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* Krankenhaus der Barmherzigen Brüder, Regensburg, Germany
University of Leipzig, Heart Center GmbH, Leipzig, Germany
Krankenhaus der Barmherzigen Brüder, Trier, Germany
Heart Center Siegburg, Siegburg, Germany
|| Midwest Cardiology Research Foundation, Riverside Methodist Hospital, Columbus, Ohio
¶ Cooper Hospital, Camden, New Jersey
# Prairie Education and Research, Springfield, Illinois
** William Beaumont Hospital, Cardiology Center, Royal Oak, Michigan

Mayo Clinic, St. Marys Hospital, Rochester, Minnesota.
Manuscript received February 8, 2007; revised manuscript received February 26, 2007, accepted February 28, 2007.
* Reprint requests and correspondence: Dr. Peter B. Sick, Krankenhaus der Barmherzigen Brüder Regensburg, Medizinische Klinik III/Kardiologie, Prüfeningerstrasse 86, 93049 Regensburg, Germany. (Email: peter.sick{at}barmherzige-regensburg.de).
Objectives: This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial fibrillation (AF) to prevent thromboembolic stroke.
Background: Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90% of them are in the LAA.
Methods: The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45 days and 6 months with annual clinical follow-up thereafter.
Results: Sixty-six patients underwent device implantation. Mean follow-up was 740 ± 341 days. At 45 days, 93% (54 of 58) devices showed successful sealing of LAA according to protocol. Two patients experienced device embolization, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modification of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experienced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Autopsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during follow-up despite >90% of patients with discontinuation of anticoagulation.
Conclusions: Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized study is ongoing comparing oral anticoagulation with percutaneous closure.
| ||||||
Related Article
J. Am. Coll. Cardiol. 2007 49: 1496-1497.
This article has been cited by other articles:
![]() |
Y. L Bayard, S. H Ostermayer, and H. Sievert Alternatives to warfarin in atrial fibrillation: drugs and devices Heart, September 1, 2008; 94(9): 1113 - 1116. [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF] |
||||
![]() |
J. Koebe and P. Kirchhof Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation Europace, April 1, 2008; 10(4): 433 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stollberger and J. Finsterer WATCHMAN for Stroke Prevention: An Out-of-Date Procedure J. Am. Coll. Cardiol., August 28, 2007; 50(9): 914 - 914. [Full Text] [PDF] |
||||
![]() |
P. Sick Reply J. Am. Coll. Cardiol., August 28, 2007; 50(9): 914 - 915. [Full Text] [PDF] |
||||
![]() |
P. C. Block Watching the Watchman J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1496 - 1497. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |